Multiples.
Sectors/Medical Devices & Diagnostics/Diagnostics & Imaging
⧉ MRI imaging stack › MRI System OEMs

Hyperfine, Inc.

HYPRUS

Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communication system. It serves intensive care units, neurology offices, emergency departments, and comprehensive and primary stroke accredited facilities through direct sales and distributors in the United States, Canada, the United Kingdom, other European and Middle Eastern markets, Australia, and New Zealand. The company was founded in 2014 and is based in Guilford, Connecticut.

Founded2014IPO year2021As of2026-08-04
Market Cap
$83M
Enterprise Value
$56M
EV / LTM Revenue
4.1x
EV / NTM Revenue
2.4x
Trading multiples

Enterprise value over trailing (LTM) vs. forward (NTM) fundamentals. Click an LTM cell to chart it.

LTM
trailing
NTM
forward
Revenue
2.4x
Gross Profit
4.6x
EBITDA
—
Classification
Sector
Medical Devices & Diagnostics
Sub-sector
Diagnostics & Imaging
Listing
HYPR
Country
US
Historical valuation & fundamentals

EV / LTM Revenue

Open full Medical Devices & Diagnostics regression →

Annual financials & analyst forecasts

$MCY2021CY2022CY2023CY2024CY2025CY2026ECY2027E
Revenue YoY—355%62%17%5%49%30%
Revenue$1M$7M$11M$13M$14M$20M$26M
Gross Profit($1M)$0.91M$5M$6M$7M——
Gross Profit Margin-78.0%13.3%43.1%45.7%49.8%——
EBITDA($64M)($72M)($43M)($40M)($34M)($20M)($26M)
EBITDA Margin-4287.2%-1058.8%-391.4%-308.1%-251.2%-100.0%-100.0%
EBIT($65M)($74M)($48M)($43M)($37M)($20M)($26M)
Net Income($65M)($73M)($44M)($41M)($36M)($33M)($32M)
Free Cash Flow($80M)($73M)($43M)($39M)($29M)——
FCF Margin-5328.7%-1070.2%-386.3%-303.7%-214.8%——
Short-Term Debt$0M$0M$0M$0M$0M——
Long-Term Debt$0M$0M$0M$0M$0M——
Cash & Cash Equivalents$0.19M$118M$75M$38M$35M——
Net Debt($0.19M)($118M)($75M)($38M)($35M)——
Net Debt / EBITDA———————
Rule of 40—-714.7%-324.4%-286.9%-209.6%——
Figures in $M. True calendar years (Jan–Dec) built from quarterly data — income & cash-flow lines summed across the four quarters, balance sheet as of year-end. E columns are calendarized analyst consensus — gross profit, cash flow and balance-sheet lines are not estimated. Net debt = short-term debt + long-term debt − cash & cash equivalents; Rule of 40 = YoY revenue growth + FCF margin.